AN2 Therapeutics to pause lung disease study enrollment (updated)

AN2 Therapeutics

12/02/2024 12:04

(Adds details, background in paragraphs 2-4)
       Feb 12 (Reuters) - AN2 Therapeutics  ANTX.O  said on
Monday it will pause further enrollment in a mid-to-late-stage
study testing its experimental drug to treat a type of bacterial
lung infection, citing potentially lower-than-expected efficacy.
    It clarified the pause was not due to any safety concerns. 
    The company was conducting a mid-stage study testing
epetraborole, a once-daily oral drug to treat MAC lung disease,
caused by bacterial infection. 
    AN2 said the decision to pause enrollment will give time to
further evaluate the study data and it expects to announce
top-line results from the study in the summer.

 (Reporting by Mariam Sunny And Sneha S K in Bengaluru ; Editing
by Krishna Chandra Eluri)
 ((Mariam.ESunny@thomsonreuters.com;))